<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:mpath ids='MPATH_177'>Angiogenesis</z:mpath>, the recruitment and growth of blood vessels, is a process central to the growth of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>One of the key mediators of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> is the vascular endothelial growth factor (VEGF) family of ligands </plain></SENT>
<SENT sid="2" pm="."><plain>An antibody to VEGF-A, bevacizumab, has demonstrated a survival benefit in conjunction with <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based doublet chemotherapy in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Aflibercept (VEGF Trap) is a recombinant VEGF receptor-antibody protein fusion with higher affinity for VEGF-A than bevacizumab, plus affinity for VEGF-B and placental growth factor (PlGF) </plain></SENT>
<SENT sid="4" pm="."><plain>AREAS COVERED: This article reviews recent clinical trials investigating the role of aflibercept in the treatment of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, both published in the literature and those for which preliminary data have been presented at major scientific meetings </plain></SENT>
<SENT sid="5" pm="."><plain>EXPERT OPINION: Aflibercept has proven Phase III efficacy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, but in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, large clinical trials have not yielded positive results </plain></SENT>
<SENT sid="6" pm="."><plain>There remains hope that identification of biomarkers of response will one day help select patients most likely to benefit from antiangiogenesis therapy </plain></SENT>
</text></document>